Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 20,600 shares, an increase of 32.1% from the March 15th total of 15,600 shares. Based on an average trading volume of 2,200 shares, the […]
Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 20,600 shares, an increase of 32.1% from the March 15th total of 15,600 shares. Based on an average daily volume of 2,200 shares, the […]
Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 20,600 shares, a growth of 32.1% from the March 15th total of 15,600 shares. Based on an average daily volume of 2,200 shares, the […]
Proprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other tissues.
New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagersTri-specific T-cell engager resulted.